LEADER 01059nam0-2200325---450-
001 990008493630403321
005 20070719105556.0
010   $a0-443-04655-7
035   $a000849363
035   $aFED01000849363
035   $a(Aleph)000849363FED01
035   $a000849363
100   $a20070328d1991----km-y0itay50------ba
101 0 $aeng
105   $a--------001yy
200 1 $aDrug safety$ea shared responsibility$fwritten by International Drug Surveillance Department, Glaxo Group Research$gforeword by Michael D. Rawlins
210   $aLondon$cChurchill Livingstone$d1991
215   $a126 p.$d23 cm
610 0 $aFarmaci$aEffetti dannosi$aPrevenzione
610 0 $aFarmacovigilanza
676   $a363.1946
702  1$aRawlins,$bMichael D.
710 02$aGlaxo Group Research limited :$bInternational drug surveillance department$0301066
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990008493630403321
952   $a80 XXIV 81 CFT (27)$bCFT 576$fFFABC
959   $aFFABC
996   $aDrug safety$9731200
997   $aUNINA